Health
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients – News-Medical.Net
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at…
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude…
-
Noosa News19 hours agoGaming policy on council’s agenda
-
Noosa News22 hours agoRiders in good hands | Noosa Today
-
Business20 hours agoRanking the best “Magnificent Seven” stocks to buy for 2026. Here’s my No. 5 pick.
-
Noosa News16 hours agoJetstar flights resume across Australia after Airbus A320 software issue identified